



## **2021 EFPIA Patient Organisation Methodological Note – Eli Lilly and Company – Ireland**

Patient organisations are a key driving force in allowing the pharma industry to become more patient centric; they provide valuable insight into the development and improvement of innovative treatments and practices.

Relationships between pharma companies and patient organisations are regulated through the EFPIA Code and national industry codes to enforce public disclosure of any collaboration. It is integral to follow these guidelines to meet and maintain high standards of transparency and integrity between the pharma industry and patient organisations across Europe.

This Methodological Note is intended to serve as supporting documentation for the Lilly patient organisation report published annually. It underlines the rationale for interactions between Lilly and patient organisations and describes the methods applied to meet the reporting requirements outlined in the EFPIA Disclosure Code and local transparency guidelines where applicable.

Patient Organisations are described as a non-for-profit legal person/entity (including the umbrella organisation to which it belongs), mainly composed of patients and/or caregivers, that represents and/or supports the needs of patients and/or caregivers and which business address, place of incorporation or primary place of operation is in Europe.

The patient organisation report for each country will outline:

- The type of support Lilly are providing to the patient organisation i.e. – financial, indirect, or significant non-financial support
- The nature of funding or project description for every transaction
- The transaction amount in local currency if there is a monetary value attached

### **Cross Border Transfer of Values**

Lilly define cross-border ToV as a Transfer of Value to a patient organisation where the Lilly division providing the funding is based outside of the country of the benefitting patient organisation. These ToVs are disclosed in the country where the patient organisation has been registered. These cross border ToVs are included in the relevant patient organisation reports as ‘International support’.

### **Charitable Donations**

Every year Lilly employees under the guidance of the Corporate Social Responsibility team engage in a variety of fundraising activities and initiatives for charitable organisations, to which Lilly may also contribute. These gift-matching donations are not within the scope of documented funding arrangements or partnerships with Patient Organisations and are therefore not included in these disclosures.

### **COVID-19**

As per EFPIA guidance, all EFPIA Member Companies must provide detailed explanations on the consequences of COVID-19 on the disclosure data in their methodological note, if applicable.

It is important to ensure that any transactions arising due to the pandemic are reflected in the patient org report if they are deemed reportable and have a monetary value or significant non-financial value associated with them. For example, there may have been an increase in virtual campaigns or collaborations with Patient organisations to facilitate partnership during travel restrictions. It is important these are reported to ensure Lilly is adhering to the ethical guidance in light of COVID-19, which has been reflected in the updated EFPIA Code of practice.

### **Report Regeneration**

Regarding report corrections, once reports have been published, data corrections may require updates to reports that are publicly available. Once revisions have been made, the publicly available reports may need to be updated to reflect the changes.

**Published Date:** The publication date equals the date the report is generated via internal systems.

This data will remain published for 3 years in the public domain.